Carboplatin Dosage Calculator

What Is Carboplatin?

Carboplatin is a platinum-based chemotherapy drug used to treat various cancers. It is a second-generation platinum compound developed as an analog of cisplatin with a similar mechanism of action but an improved toxicity profile. Carboplatin works by forming cross-links with DNA, disrupting DNA replication and transcription, ultimately leading to cancer cell death (apoptosis).

Unlike most chemotherapy agents that are dosed based on body surface area (BSA), carboplatin is uniquely dosed based on renal function (GFR) and a target area under the concentration-time curve (AUC). This approach was developed because carboplatin is primarily eliminated by the kidneys, and its clearance correlates closely with GFR.

The Calvert Formula

The Calvert formula, published by Calvert et al. in 1989, is the standard method for calculating carboplatin doses. It directly relates the dose to the desired drug exposure (AUC) and the patient's renal function:

The constant of 25 represents the average non-renal clearance of carboplatin (primarily through hepatic metabolism and other routes). This value was derived from pharmacokinetic studies and remains consistent across most patients.

Understanding AUC

AUC (Area Under the Curve) represents the total drug exposure over time and is measured in mg·min/mL. In carboplatin dosing, the target AUC is selected based on the treatment regimen:

Target AUC	Typical Use	Setting
AUC 2	Weekly low-dose regimens	Radiosensitization
AUC 4	Combination chemotherapy (reduced dose)	Dose reductions, elderly patients
AUC 5	Combination chemotherapy (standard)	Ovarian, lung, head & neck cancers
AUC 6	Combination or single-agent therapy	Ovarian cancer, testicular cancer
AUC 7	Single-agent therapy (aggressive)	Previously untreated ovarian cancer

Higher AUC values result in greater drug exposure and potentially better efficacy, but also increased toxicity — particularly myelosuppression (bone marrow suppression). The target AUC is selected by the oncologist based on the specific cancer type, treatment protocol, and patient tolerance.

GFR Estimation Methods

Accurate GFR estimation is crucial for correct carboplatin dosing. Several methods are available:

• Direct measurement: Using radioisotope methods (⁵¹Cr-EDTA, ⁹⁹ᵐTc-DTPA) — the gold standard but impractical for routine use
• 24-hour urine creatinine clearance: Cumbersome and subject to collection errors
• Cockcroft-Gault equation: Most commonly used in clinical practice for carboplatin dosing
• CKD-EPI or MDRD: Designed for eGFR staging, not validated for drug dosing; report normalized values (mL/min/1.73m²)

Cockcroft-Gault Equation

The Cockcroft-Gault (CG) equation is the most widely used method for estimating creatinine clearance in carboplatin dosing:

Key considerations when using Cockcroft-Gault:

• Weight: Use actual body weight. For obese patients, some institutions use adjusted body weight or ideal body weight — check institutional protocols.
• Creatinine units: Ensure serum creatinine is in mg/dL. If reported in µmol/L, divide by 88.4 to convert.
• Low creatinine values: In cachectic or elderly patients, very low creatinine (e.g., < 0.7 mg/dL) may overestimate renal function. Some protocols round up to 0.7 mg/dL.

FDA GFR Capping

In 2010, the FDA issued a safety communication recommending that GFR be capped at 125 mL/min when calculating carboplatin doses. This was in response to reports of serious toxicities (including deaths) when doses were calculated using high GFR values estimated from low serum creatinine levels.

The capping applies primarily to patients with low serum creatinine values, which can falsely elevate estimated GFR and lead to overdosing. Key points:

• Maximum GFR in Calvert formula: 125 mL/min
• With AUC 6: maximum dose = 6 × (125 + 25) = 900 mg
• Applies when using estimated (not directly measured) GFR
• Particularly important for patients with low muscle mass or low serum creatinine

Common Indications

Carboplatin is used in the treatment of multiple cancer types, often in combination with other agents:

Cancer Type	Common Regimen	Typical AUC
Ovarian cancer	Carboplatin + Paclitaxel	AUC 5–6
Non-small cell lung cancer	Carboplatin + Paclitaxel/Pemetrexed	AUC 5–6
Small cell lung cancer	Carboplatin + Etoposide	AUC 5
Testicular cancer	Single-agent carboplatin (stage I seminoma)	AUC 7
Head & neck cancer	Carboplatin + 5-FU + Cetuximab	AUC 5
Endometrial cancer	Carboplatin + Paclitaxel	AUC 5–6

Side Effects and Monitoring

The dose-limiting toxicity of carboplatin is myelosuppression, particularly thrombocytopenia (low platelets). Other significant side effects include:

• Thrombocytopenia: Nadir typically occurs at days 14–21; dose-dependent and correlates with AUC
• Neutropenia: Increases infection risk; may require G-CSF support
• Nausea and vomiting: Moderate emetogenic potential; requires antiemetic prophylaxis
• Nephrotoxicity: Much less than cisplatin, but renal function should be monitored
• Ototoxicity: Less frequent than cisplatin; monitor with audiometry in at-risk patients
• Peripheral neuropathy: Can be cumulative, especially with concurrent taxanes
• Hypersensitivity reactions: Risk increases after multiple cycles; can be severe

Monitoring requirements include: CBC with differential before each cycle, serum creatinine, BUN, electrolytes, liver function tests, and assessment of performance status.

Special Populations

Obese Patients

For obese patients (BMI > 30), the choice of weight for Cockcroft-Gault estimation is debated. Options include actual body weight, ideal body weight, or adjusted body weight. Institutional protocols vary — follow your facility's guidelines.

Elderly Patients

Elderly patients may have reduced muscle mass leading to low serum creatinine that overestimates renal function. GFR capping is particularly important in this population.

Renal Impairment

Patients with significantly impaired renal function (GFR < 30 mL/min) may not be candidates for carboplatin. Dose adjustments or alternative agents should be considered. If used, careful monitoring is essential.